X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
female (86) 86
male (86) 86
middle aged (78) 78
adult (75) 75
index medicus (73) 73
hepatitis c, chronic - drug therapy (58) 58
hepacivirus - genetics (53) 53
antiviral agents - therapeutic use (51) 51
gastroenterology & hepatology (50) 50
genotype (50) 50
aged (49) 49
treatment outcome (48) 48
drug therapy, combination (45) 45
hepatitis c (39) 39
ribavirin (36) 36
interferon-alpha - therapeutic use (34) 34
antiviral agents - adverse effects (33) 33
ribavirin - therapeutic use (33) 33
hepatitis c, chronic - virology (30) 30
polyethylene glycols - therapeutic use (29) 29
hepatitis c virus (28) 28
antiviral agents - administration & dosage (27) 27
gastroenterology and hepatology (27) 27
recombinant proteins (27) 27
young adult (27) 27
double-blind method (26) 26
viral load (26) 26
interferon (24) 24
care and treatment (23) 23
plus ribavirin (23) 23
ribavirin - administration & dosage (23) 23
ribavirin - adverse effects (23) 23
rna, viral - blood (23) 23
abridged index medicus (21) 21
adolescent (21) 21
interferon-alpha - administration & dosage (21) 21
hepacivirus - drug effects (19) 19
hepatitis c - drug therapy (19) 19
interferon-alpha - adverse effects (19) 19
polyethylene glycols - administration & dosage (19) 19
telaprevir (18) 18
therapy (18) 18
virus-infection (18) 18
chronic hepatitis-c (17) 17
health aspects (17) 17
hepatitis (17) 17
biological response modifiers (16) 16
hiv (16) 16
dose-response relationship, drug (15) 15
polyethylene glycols - adverse effects (15) 15
antiviral agents (14) 14
genetic aspects (14) 14
hiv infections - complications (14) 14
recombinant proteins - therapeutic use (14) 14
sofosbuvir (14) 14
hcv (13) 13
hepatitis c, chronic - complications (13) 13
medicine, general & internal (13) 13
pharmacology & pharmacy (13) 13
combination therapy (12) 12
drug administration schedule (12) 12
drug therapy (12) 12
genotype & phenotype (12) 12
logistic models (12) 12
boceprevir (11) 11
cirrhosis (11) 11
infectious diseases (11) 11
liver cirrhosis (11) 11
recombinant proteins - administration & dosage (11) 11
uridine monophosphate - analogs & derivatives (11) 11
antiviral agents - pharmacokinetics (10) 10
combination (10) 10
hepacivirus - classification (10) 10
peginterferon alpha-2a (10) 10
sustained virological response (10) 10
antiviral therapy (9) 9
article (9) 9
chronic hepatitis c (9) 9
clinical trials (9) 9
hepatitis c, chronic - diagnosis (9) 9
hiv infections - drug therapy (9) 9
infection (9) 9
liver - pathology (9) 9
protease inhibitors (9) 9
research (9) 9
rna (9) 9
uridine monophosphate - therapeutic use (9) 9
viral nonstructural proteins - antagonists & inhibitors (9) 9
virology (9) 9
aged, 80 and over (8) 8
analysis (8) 8
dosage and administration (8) 8
fibrosis (8) 8
hepacivirus - isolation & purification (8) 8
hispanic americans (8) 8
human immunodeficiency virus--hiv (8) 8
insulin resistance (8) 8
liver (8) 8
prospective studies (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 18, pp. 1685 - 1694
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9956, pp. 1756 - 1765
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2013, Volume 13, Issue 5, pp. 401 - 408
Summary Background Protease inhibitors have improved treatment of infection with hepatitis C virus (HCV), but dosing, a low barrier to resistance, drug... 
Infectious Disease | PSI-7977 | INFECTIOUS DISEASES | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | BOCEPREVIR | INHIBITORS | Recombinant Proteins - therapeutic use | Uridine Monophosphate - administration & dosage | Nausea - chemically induced | Humans | Middle Aged | Hepatitis C, Chronic - virology | Hepacivirus - pathogenicity | Male | Secondary Prevention | Polyethylene Glycols - therapeutic use | Young Adult | Time Factors | Ribavirin - administration & dosage | Adult | Female | Headache - chemically induced | Uridine Monophosphate - therapeutic use | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | RNA, Viral - analysis | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Adolescent | Liver Cirrhosis - pathology | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Protease inhibitors | Proteases | Gastrointestinal diseases | Clinical trials | Product development | Genetic aspects | Interferon | Hepatitis C | Health aspects | Liver cirrhosis | Viral antigens
Journal Article
Diabetes, ISSN 0012-1797, 12/2012, Volume 61, Issue 12, pp. 3314 - 3321
Journal Article
Hepatology, ISSN 0270-9139, 12/2012, Volume 56, Issue 6, pp. 2039 - 2050
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1867 - 1877
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2014, Volume 370, Issue 3, pp. 211 - 221
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2013, Volume 368, Issue 20, pp. 1878 - 1887
Journal Article